Cite
HARVARD Citation
Holmes, F. et al. (2023). Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. European journal of cancer. pp. 48-59. [Online].